Characterization of Extramedullary Disease (EMD) Response to CD19 Targeted Chimeric Antigen Receptor T-Cells (CART) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Multi-Site, Retrospective Cohort Review

CD19 CART are highly effective in eradicating bone marrow (BM) B-ALL, but efficacy in EMD is less clear. Recent data suggests that response in central nervous system (CNS) disease may be comparable to BM disease without increased toxicity. Data using CART in non-CNS EMD is limited to small retrospective analyses with demonstration of mixed BM/EMD responses. An improved understanding of CART efficacy in EMD is needed to help inform management decisions.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Alexander W. Rankin, Regina M. Myers, Adam Lamble, Emily M. Hsieh, Sara Silbert, Seth M. Steinberg, Colleen Annesley, Bonnie Yates, Samuel John, Jennifer Sheppard, Lee Chen, Daniel W. Lee, Amanda DiNofia, Stephan A. Grupp, Lia Gore, Mike A. Pulsipher, Nir Tags: 104 Source Type: research